328 related articles for article (PubMed ID: 37480884)
21. Cellular therapy: Immune-related complications.
Oved JH; Barrett DM; Teachey DT
Immunol Rev; 2019 Jul; 290(1):114-126. PubMed ID: 31355491
[TBL] [Abstract][Full Text] [Related]
22. Management of CAR T-cell Related Toxicities: What did the Learning Curve Teach us so Far?
Murthy HS; Yassine F; Iqbal M; Alotaibi S; Moustafa MA; Kharfan-Dabaja MA
Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):100-111. PubMed ID: 36395496
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
24. Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies.
Dos Santos DMC; Rejeski K; Winkelmann M; Liu L; Trinkner P; Günther S; Bücklein VL; Blumenberg V; Schmidt C; Kunz WG; Von Bergwelt-Baildon M; Theurich S; Subklewe M
Haematologica; 2022 Sep; 107(9):2096-2107. PubMed ID: 35172565
[TBL] [Abstract][Full Text] [Related]
25. Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy.
Ding S; Chen R; Wang L; Zu C; Zhou X; Zhang J; Zhang M; Jin A; Wang T; Hu Y
BMC Cancer; 2023 Nov; 23(1):1055. PubMed ID: 37919691
[TBL] [Abstract][Full Text] [Related]
26. Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma.
Wang X; Zhao L; Wang J; Yao Y; Wang J; Ji S; Hua T; Wang S; Cheng H; Shi M; Li Z; Zeng L; Zheng J; Xu K; Cao J
Front Immunol; 2022; 13():814548. PubMed ID: 35572513
[TBL] [Abstract][Full Text] [Related]
27. Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.
Ma S; Li H; Zhou D; Zhang X; Shi M; Cao J; Qi Y; Xia J; Liu Y; Wang X; Li D; Sang W; Yan Z; Zhu F; Sun H; Cheng H; Zheng J; Xu K; Li Z; Qi K; Wang Y
Cytotherapy; 2023 Jun; 25(6):653-658. PubMed ID: 36907717
[TBL] [Abstract][Full Text] [Related]
28. Chimeric antigen receptor T cell therapy and nephrotoxicity: From diagnosis to treatment strategies.
Zhou H; Yang M; Cui L; Jiang J
Int Immunopharmacol; 2020 Dec; 89(Pt B):107072. PubMed ID: 33059198
[TBL] [Abstract][Full Text] [Related]
29. Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma.
Zhou J; Zhang Y; Shan M; Zong X; Geng H; Li J; Chen G; Yu L; Xu Y; Li C; Wu D
Front Immunol; 2022; 13():997589. PubMed ID: 36131934
[TBL] [Abstract][Full Text] [Related]
30. [Establishment of a cytokine release syndrome associated with chimeric antigen receptor T cell treatment in SCID/Beige mice model].
Shan JQ; Nan SF; Li F; Shen CY; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1248-1254. PubMed ID: 34915632
[No Abstract] [Full Text] [Related]
31. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
[TBL] [Abstract][Full Text] [Related]
32. Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma.
Zhang Q; Zu C; Jing R; Feng Y; Zhang Y; Zhang M; Lv Y; Cui J; Zhou L; Meng Y; Wang L; Cen Z; Chang AH; Hu Y; Huang H
Front Immunol; 2023; 14():1125357. PubMed ID: 37215107
[TBL] [Abstract][Full Text] [Related]
33. Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients.
Ishii K; Pouzolles M; Chien CD; Erwin-Cohen RA; Kohler ME; Qin H; Lei H; Kuhn S; Ombrello AK; Dulau-Florea A; Eckhaus MA; Shalabi H; Yates B; Lichtenstein DA; Zimmermann VS; Kondo T; Shern JF; Young HA; Taylor N; Shah NN; Fry TJ
J Clin Invest; 2020 Oct; 130(10):5425-5443. PubMed ID: 32925169
[TBL] [Abstract][Full Text] [Related]
34. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
Gazeau N; Liang EC; Wu QV; Voutsinas JM; Barba P; Iacoboni G; Kwon M; Ortega JLR; López-Corral L; Hernani R; Ortiz-Maldonado V; Martínez-Cibrian N; Martinez AP; Maziarz RT; Williamson S; Nemecek ER; Shadman M; Cowan AJ; Green DJ; Kimble E; Hirayama AV; Maloney DG; Turtle CJ; Gauthier J
Transplant Cell Ther; 2023 Jul; 29(7):430-437. PubMed ID: 37031746
[TBL] [Abstract][Full Text] [Related]
35. Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia.
Hong F; Shi M; Cao J; Wang Y; Gong Y; Gao H; Li Z; Zheng J; Zeng L; He A; Xu K
J Cell Mol Med; 2021 Dec; 25(24):11063-11074. PubMed ID: 34734474
[TBL] [Abstract][Full Text] [Related]
36. Chimeric antigen receptor T-cells safety: A pharmacovigilance and meta-analysis study.
Dolladille C; Ederhy S; Ezine E; Choquet S; Nguyen LS; Alexandre J; Moslehi JJ; Dechartres A; Salem JE
Am J Hematol; 2021 Sep; 96(9):1101-1111. PubMed ID: 34057232
[TBL] [Abstract][Full Text] [Related]
37. Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome.
Stahl K; Schmidt BMW; Hoeper MM; Skripuletz T; Möhn N; Beutel G; Eder M; Welte T; Ganser A; Falk CS; Koenecke C; David S
J Crit Care; 2020 Jun; 57():124-129. PubMed ID: 32113143
[TBL] [Abstract][Full Text] [Related]
38. Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy.
Liu Y; Chen X; Wang D; Li H; Huang J; Zhang Z; Qiao Y; Zhang H; Zeng Y; Tang C; Yang S; Wan X; Chen YH; Zhang Y
J Immunother; 2018; 41(9):406-410. PubMed ID: 30198955
[TBL] [Abstract][Full Text] [Related]
39. Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following Chimeric Antigen Receptor T Cell Therapy.
Read JA; Rouce RH; Mo F; Mamonkin M; King KY
Transplant Cell Ther; 2023 Mar; 29(3):165.e1-165.e7. PubMed ID: 36592718
[TBL] [Abstract][Full Text] [Related]
40. The immunologic aspects of cytokine release syndrome and graft versus host disease following CAR T cell therapy.
Mansouri V; Yazdanpanah N; Rezaei N
Int Rev Immunol; 2022; 41(6):649-668. PubMed ID: 34607523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]